Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -47.32M | -79.05M | -71.90M | -91.25M | -111.66M |
| Total Depreciation and Amortization | 10.40M | 10.42M | 12.64M | 11.68M | 12.23M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.91M | 9.44M | 13.99M | 9.41M | 23.09M |
| Change in Net Operating Assets | -35.83M | -12.88M | -7.29M | -8.53M | 8.90M |
| Cash from Operations | -60.84M | -72.07M | -52.57M | -78.70M | -67.45M |
| Capital Expenditure | -5.44M | -6.61M | -9.32M | -10.84M | -7.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.61M | 18.00M | 10.10M | 27.86M | 21.30M |
| Cash from Investing | -74.05M | 11.39M | 775.00K | 17.01M | 13.84M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.45M | 98.51M | 56.62M | 88.52M | 13.73M |
| Repurchase of Common Stock | -1.17M | -4.18M | -445.00K | -466.00K | -504.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 49.29M | 94.34M | 56.17M | 88.06M | 13.23M |
| Foreign Exchange rate Adjustments | -124.00K | -213.00K | 577.00K | -680.00K | 739.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -85.73M | 33.44M | 4.96M | 25.69M | -39.64M |